Amgen (NASDAQ:AMGN) Updates FY 2025 Earnings Guidance

Key Points

• Amgen has issued its FY 2025 earnings guidance with EPS projected between $20.200-$21.300, slightly below the consensus estimate of $20.889, and revenue forecasted at $35.0-$36.0 billion, which is also close to the consensus estimate of $35.3 billion.
• The company's stock price decreased by 0.6% to $300.22, with a trading volume of over 2 million shares, indicating market volatility.
• Amgen announced a quarterly dividend of $2.38 per share, which is set to be paid on September 12th and represents an annualized yield of 3.2%.

Amgen (NASDAQ:AMGN - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 20.200-21.300 for the period, compared to the consensus EPS estimate of 20.889. The company issued revenue guidance of $35.0 billion-$36.0 billion, compared to the consensus revenue estimate of $35.3 billion.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AMGN shares. Royal Bank Of Canada reduced their target price on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Piper Sandler reissued an "overweight" rating and issued a $328.00 price target on shares of Amgen in a research note on Friday, June 27th. Cantor Fitzgerald restated a "neutral" rating and issued a $305.00 price target on shares of Amgen in a research note on Tuesday, June 24th. UBS Group reduced their target price on Amgen from $326.00 to $317.00 and set a "neutral" rating for the company in a report on Wednesday. Finally, Guggenheim began coverage on Amgen in a research report on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 target price on the stock. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $307.23.

Amgen Stock Down 0.0%

AMGN traded down $0.07 during trading on Thursday, hitting $284.60. 1,178,286 shares of the company's stock traded hands, compared to its average volume of 2,903,298. Amgen has a 12-month low of $253.30 and a 12-month high of $339.17. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The company's 50 day simple moving average is $293.18 and its two-hundred day simple moving average is $292.39. The stock has a market capitalization of $153.03 billion, a price-to-earnings ratio of 23.31, a PEG ratio of 2.60 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping the consensus estimate of $5.28 by $0.74. The company had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. Amgen had a return on equity of 180.66% and a net margin of 18.96%. The firm's revenue was up 9.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.97 earnings per share. Analysts predict that Amgen will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be given a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.3%. Amgen's dividend payout ratio is 77.84%.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the sale, the senior vice president directly owned 8,162 shares in the company, valued at approximately $2,364,368.16. This trade represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.76% of the company's stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Amgen stock. Brighton Jones LLC boosted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 23.5% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 27,468 shares of the medical research company's stock after buying an additional 5,226 shares during the quarter. Brighton Jones LLC's holdings in Amgen were worth $7,159,000 as of its most recent filing with the Securities & Exchange Commission. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.